尊龙凯时

客户简介

Shanghai Fosun Pharmaceutical (Group) Co., Ltd

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (referred to as "Fosun Pharmaceutical", stock code: 600196.SH, 02196.HK) was established in 1994 and is a leading medical and health industry group in China. Fosun Pharmaceutical Group's mission is to promote human health, covering the entire pharmaceutical and health industry chain, including drug manufacturing and research and development, medical services, medical devices and diagnostics, pharmaceutical distribution and retail. Among them, drug manufacturing and research and development are the core, and medical services are the development focus.

Fosun Pharmaceutical Group regards innovation and research and development as the core driving factor for enterprise development, and has established efficient chemical innovative drug platforms, biopharmaceutical platforms, high-value generic drug platforms, and cellular immune platforms in China, the United States, India, and other places. At present, Fosun Pharmaceutical Group's research and development continue to focus on the treatment fields of anti-tumor, cardiovascular system, central nervous system, blood system, metabolic and digestive system, and anti infection, and its main products occupy leading positions in their respective segmented markets.

In the field of medical services, Fosun Pharmaceutical Group has preliminarily formed a business strategic layout that combines high-end medical services in coastal developed cities, specialized and comprehensive hospitals in second and third tier cities. As of the end of 2018, a total of 4118 approved beds were held by Fosun Pharmaceutical Group, including Chancheng Hospital, Hengsheng Hospital, Zhongwu Hospital, Wenzhou Geriatric Hospital, Guangji Hospital, Jimin Hospital, Zhuhai Chancheng Hospital, and Wuhan Jihe Hospital; The affiliated hospital Harmony Home continues to maintain its brand appeal and leading position in the high-end medical field in core cities such as Beijing, Tianjin, and Shanghai.